title: [Premature immunosenescence: a pathogenetic factor in Alzheimer's disease?].
abstract: While the familial form of Alzheimer's disease (AD) is known to be entirely inherited, the etiopathogenesis of the most common late-onset form of Alzheimer's disease still remains unresolved. Among various factors, aging seems to be one of the most prominent risk factors. Moreover, a large body of evidence points to the contribution of immunological alterations in AD. The involvement of inflammatory factors in the etiopathology has been widely discussed. Moreover, an impairment of certain immune responses in AD has been observed. Presumably, premature immunosenescence may lead to inadequate immune reactions. Against this background, the development of different immunotherapeutic strategies seems to be a promising challenge for future research.
authors.affiliation: Universitätsklinik für Psychiatrie und Psychotherapie, Tübingen, Tübingen, Deutschland. elke.richartz@gmx.de
authors.forename: E
authors.initials: E
authors.lastname: Richartz-Salzburger
authors.forename: E
authors.initials: E
authors.lastname: Stransky
authors.forename: C
authors.initials: C
authors.lastname: Laske
authors.forename: N
authors.initials: N
authors.lastname: Köhler
mesh_terms: D000544:Alzheimer Disease / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D007249:Inflammation / Q000150:complications* / Q000175:diagnosis / Q000628:therapy*
references.citation: Cogn Behav Neurol. 2003 Sep;16(3):170-6
references.pmid: 14501538
references.citation: Dement Geriatr Cogn Disord. 2005;19(4):184-8
references.pmid: 15677865
references.citation: Brain Pathol. 1993 Oct;3(4):333-47
references.pmid: 8293190
references.citation: Lab Invest. 2000 Aug;80(8):1323-35
references.pmid: 10950123
references.citation: Microsc Res Tech. 2001 Jul 15;54(2):59-70
references.pmid: 11455613
references.citation: Curr Alzheimer Res. 2008 Oct;5(5):457-68
references.pmid: 18855587
references.citation: J Alzheimers Dis. 2005 Jun;7(3):221-32; discussion 255-62
references.pmid: 16006665
references.citation: Neurobiol Aging. 2000 May-Jun;21(3):383-421
references.pmid: 10858586
references.citation: Curr Opin Investig Drugs. 2007 Jul;8(7):519-24
references.pmid: 17659471
references.citation: Nature. 1999 Jul 8;400(6740):173-7
references.pmid: 10408445
references.citation: J Clin Lab Anal. 1990;4(1):16-21
references.pmid: 1968967
references.citation: Exp Gerontol. 2002 Jan-Mar;37(2-3):249-56
references.pmid: 11772510
references.citation: Am J Hum Genet. 1998 May;62(5):1003-7
references.pmid: 9545415
references.citation: Nervenarzt. 2008 Jul;79(7):832-5
references.pmid: 18542908
references.citation: Mech Ageing Dev. 1986-1987 Jan;37(3):257-64
references.pmid: 2952844
references.citation: Drugs Aging. 2003;20(2):101-13
references.pmid: 12534311
references.citation: Int J Neurosci. 1998 Sep;95(3-4):203-36
references.pmid: 9777440
references.citation: Neurobiol Aging. 2003 Jan-Feb;24(1):77-84
references.pmid: 12493553
references.citation: Clin Immunol. 2000 Apr;95(1 Pt 1):62-9
references.pmid: 10794433
references.citation: Neurology. 2007 May 29;68(22):1902-8
references.pmid: 17536046
references.citation: Neurobiol Aging. 2001 Nov-Dec;22(6):799-809
references.pmid: 11754986
references.citation: Glia. 2002 Nov;40(2):133-139
references.pmid: 12379901
references.citation: Neurology. 2001 Sep 11;57(5):801-5
references.pmid: 11552007
references.citation: CNS Neurol Disord Drug Targets. 2009 Mar;8(1):16-30
references.pmid: 19275634